[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH:8]2[C:15]3[C:14]([CH3:16])=[N:13][NH:12][C:11]=3[C:10](=[O:17])[N:9]2[C:18]2[CH:19]=[C:20]([CH3:28])[C:21]3[N:22]([C:24]([CH3:27])=[N:25][N:26]=3)[CH:23]=2)=[CH:4][CH:3]=1.I[CH:30]1[CH2:33][O:32][CH2:31]1>>[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH:8]2[C:15]3[C:14]([CH3:16])=[N:13][N:12]([CH:30]4[CH2:33][O:32][CH2:31]4)[C:11]=3[C:10](=[O:17])[N:9]2[C:18]2[CH:19]=[C:20]([CH3:28])[C:21]3[N:22]([C:24]([CH3:27])=[N:25][N:26]=3)[CH:23]=2)=[CH:4][CH:3]=1.[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH:8]2[C:15]3[C:11](=[N:12][N:13]([CH:30]4[CH2:33][O:32][CH2:31]4)[C:14]=3[CH3:16])[C:10](=[O:17])[N:9]2[C:18]2[CH:19]=[C:20]([CH3:28])[C:21]3[N:22]([C:24]([CH3:27])=[N:25][N:26]=3)[CH:23]=2)=[CH:4][CH:3]=1The title compound was prepared using an analogous procedure to that described in Example 134 using 4-(4-chlorophenyl)-5-(3,8-dimethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methyl-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one (Example 98) (200 mg, 0.509 mmol) and stirring the reaction mixture for 30 min at 80° C. after addition of 3-iodooxetane. Purification of the crude product afforded 50 mg of a 4-(4-chlorophenyl)-5-(3,8-dimethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methyl-1-(oxetan-3-yl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(1H)-one (Example 137) and 31 mg of a 4-(4-chlorophenyl)-5-(3,8-dimethyl-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methyl-2-(oxetan-3-yl)-4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one (title compound). tR: 0.79 min (LC-MS 2); ESI-MS: 449.1 [M+H]+ (LC-MS 2); Rf=0.40 (CH2Cl2/MeOH 9:1); 1H NMR (400 MHz, DMSO-d6) δ ppm 2.05 (s, 3H) 2.43 (s, 3H) 2.61 (s, 3H) 4.85-5.00 (m, 4H) 5.60-5.70 (m, 1H) 6.49 (s, 1H) 7.25-7.38 (m, 5H) 8.45 (s, 1H).
Wird geladen…